Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilucoplan for COVID-19 Acute Hypoxic Respiratory Failure
NCT04382755Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- May 2020
- Primary completion
- Dec 2020
- Modality
- Cyclic Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zilucoplan in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Change in Oxygenation Parameters (PaO2/FiO2 ratio) at Day 15. Started May 2020; status: completed.
02
Drugs
zilucoplan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04382755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382755.